The GSK, Amgen and Novo-backed cancer drug developer went public in an upsized offering priced above its range.
Nkarta Therapeutics, a US-based oncology therapy developer backed by pharmaceutical companies Amgen, Novo and GlaxoSmithKline (GSK), has raised approximately $290m in an initial public offering on the Nasdaq Global Market.
The company priced 16.1 million shares at $18 each, above a $14 to $16 range set last week when it had intended to issue 10 million shares.
Underwriters Cowen, Evercore Group, Stifel Nicolaus and Mizuho Securities have the 30-day option to buy up to 2.1 million additional shares…
